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Abstract: Drug-related problems (DRPs) can reduce the potential clinical benefits of treatment with medicines and waste 
valuable resources. No previous studies were published to examine the nature and frequency of drug related problems 
among hospitalized patients in Palestinian hospitals. Methodology: Prospective observational study was conducted to 
report and record the natural and frequency of drug related problems in two general hospitals. Results: The study included 
212 patients, 54.4 % female, with a mean age 62.2 (±10.6 SD). 88% of the patients were reported with one or more DRPs, 
with an average of 1.9 DRPs per patient were found. The most prevalent DRP was incorrect dosing regimen which was 
represented by (22.2%), followed by drug-drug interaction (19.4%), drugs need laboratory tests (15.2%). Ceftriaxone, 
warfarin, enoxapirin and dogixin were the drugs causing most frequent DRPs. The drug groups causing most DRPs were 
anti-infective agents, anti-thrombotic agents and non-steroidal anti-inflammatory agents. Once discovered, the majority of 
DRPs (71.6%) were accepted by the physicians and solved immediately, while 11.5 % of pharmacist advice was not 
approved. Multiple regression analysis indicated that the number of medications (RR 1.99; 95% CI 1.31-3.76) and the 
number of medical conditions (RR 1.81; 95% CI 1.11-3.13) independently predicted the number of DRPs. Conclusion: 
DRPs in general hospitals are frequent, serious and predictable. Most of the problems identified as DRPs by the 
pharmacists were accepted by the physicians and solved. Pharmacists in the hospital setting are well suited to identify and 
resolve DRPs.  
Keywords: DRPs, Pharmacist intervention, hospital setting, adverse drug reaction, Palestine.  
INTRODUCTION 
 Drug therapy is growing more complex, thus making 
appropriate drug prescribing increasingly challenging. Many 
patients do not receive the intended beneficial effects of their 
treatment due to drug-related problems (DRPs) [1]. DRPs 
cause both unnecessary suffering and huge expenditures to 
society, because they necessitate extra doctor’s visits and 
hospitalizations [2].  
 During the last decade, several studies have been 
published highlighting the significance of adverse drug 
reactions in hospitalized patients in terms of frequency, [3-6] 
consequences for the affected patients [7-9] and costs for the 
hospitals [10-12]. DRPs include all issues that can potentially 
affect the success of pharmacotherapy in a given patient, in 
particular medication errors, adverse drug events and adverse 
drug reactions [9]. A review of the literature from 1990 to 
2005 found that on average 8% of hospitalized patients 
experience an adverse drug event (ADE), and 5-10% of all 
drug prescriptions or drug applications are erroneous [13]. 
As an example, it has been reported that 14.6% of internal  
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medicine patients experience ADEs. Similarly, 12% to  
17% of hospitalized patients experience ADE after discharge 
[14, 15]. Older people are particularly vulnerable because of 
their increased prevalence of chronic diseases and drug 
consumption. The associations of these factors with patient 
metabolic changes with age predispose older people to suffer 
drug-drug interactions and adverse drug events, especially as 
they generally have more hospital admissions and discharges 
[16, 17]. 
 Literature reports indicate that the most common types of 
DRPs were: wrong dosage, inappropriate schedule and 
missing information. More detailed investigations show  
that DRP may stem from: non-compliance [18, 19], lack of 
knowledge about the medication [18] adverse drug events 
[20] drug interactions [21, 22] dosage problems, and 
practical problems [20]. Events associated with such DRPs 
include changes in drug therapy following hospital 
discharge, patient’s cognition and poly-pharmacy [18, 20]. 
 Pharmacy practitioners have a key responsibility to 
respond to patient DRPs. For example, Benrimoj et al. 
demonstrated the value of clinical interventions in Australian 
community pharmacies in terms of both the quality of care 
and cost savings [23]. Favorable clinical and economic 
outcomes of pharmaceutical care in ambulatory patients have 
also been shown by Strand et al [24]. 
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 There is a perception in the Palestinian health care 
system that DRPs are common in Palestinian community, yet 
no studies were conducted to quantitate this problem. 
Furthermore, the fact that the health care system in the 
general does not involve an active role for the pharmacists in 
hospitals, suggests that the prevalence of DRP may be high. 
As such, a study to quantitate DRP in Palestine was deemed 
necessary. The objective of the study was to examine the 
nature and frequency of drug related problems among 
hospitalized patients and to evaluate the impact of the 
pharmacist in identifying medication related problems.  
METHODS 
Patients and Design 
 This prospective multicenter study was approved by the 
Committee for Clinical Research, Hospital Administration 
Department, Ministry of Health, Palestine. From May to 
November 2011, expert clinical pharmacists identified DRPs 
and recorded the pharmacist’s advice on drug therapy. The 
study was performed in two medical wards at Al-Watani 
general hospital and two medical wards at Tulkarm general 
hospital (North Palestinian Territories). For participation  
we chose wards that had clinical pharmacists joining 
multidisciplinary therapeutic teams. All patients admitted to 
the participating wards were consecutively included, while 
readmissions of patients who already had been enrolled were 
excluded. Information on possible risk factors such as age, 
gender, number of drugs used at admission, total number of 
clinical/pharmacological risk factors and type of department 
were recorded and analyzed.  
Classification of Drugs and DRPs  
 The drugs were classified according to the Anatomical 
Therapeutic Chemical (ATC) classification system [25]. The 
DRPs were defined as ‘‘An event or circumstance involving 
drug therapy that actually or potentially interferes with 
desired health outcomes” [26]. The classification of DRPs is 
shown in Table 1 and was compiled according to a modified 
version of Strand et al. [27]. For the adverse drug reactions 
ADRs and drug interactions, only those graded as important, 
were included. An independent assessment team was 
appointed, consisting of three specialists in hospital 
pharmacy with long experience as clinical pharmacists. The 
team retrospectively assessed and assigned DRPs to their 
categories after each of the team members had undertaken an 
individual evaluation. If the individual judgment differed, 
the case was discussed and consensus was reached. 
Data Collection and Response to Pharmacist’s Advice  
 A special data collecting form was designed by the 
investigators for a structured patient information collection. 
The form was designed, tested and found applicable for the 
participating departments. Clinical pharmacists collected  
the data from medical charts, medical records, physicians’ 
ward rounds and from the multidisciplinary meetings where 
each patient was discussed with regard to diagnosis and 
management. 
 The main section was designed to record all the data 
regarding the patient medication, dates and times that a 
prescription was written, names of medication, dosage 
forms, doses, dosage regimens, starting and stopping dates, if 
applicable, instructions and potential drug-drug interactions. 
Demographic and medical information about patients was 
obtained from flow sheets and medication administration 
records. Laboratory results and results of diagnostic tests 
were used as necessary. 
 The collected data were reviewed by the investigational 
pharmacists and rechecked with investigational clinical team. 
The investigational pharmacists participated in the process  
of evaluation used a standard set of definitions related to 
drug related problems. As primary reference sources, the 
Palestinian Registered Product List, Drug Information 
Handbook, 21st edition the Physician’s Desk Reference  
were used. 
 Responses to pharmacist advice were recorded in three 
categories: ‘‘Fully accepted’ ’which indicates immediate 
acceptance by the physician and action taken. ‘‘Rejected ’’ 
which indicates that the physician did not approve the 
pharmacist proposal and no action was taken. ‘‘Partially 
accepted’’ which indicates agreement by the physician, who 
took notice, but no immediate action was taken.  
Data Analysis  
 All data were coded and analyzed using the SPSS 
program for Windows 16.0 (SPSS Inc, Chicago, IL). 
Descriptive statistics are shown as means with range or 
standard errors. Statistical comparisons were done by the 
Mann-Whitney for nominal continuous data, and the Chi-
squared (χ2) test for categorical. The multivariate analysis 
was employed by the backward logistic regression method in 
order to assess the influence of number of diseases, ward 
type and number of medications on the number of DRPs 
identified. In the first stage of regression, we utilized 
variables for which the p-value in the univariate analysis was 
less than 0.1. For all analyses, a probability value of less than 
0.05 was considered statistically significant.  
Table 1. Classification of a Drug-related Problem 
1. The need for an additional drug 
2. Unnecessary drug 
3. Non-optimal drug, including drug formulation 
4. Non-optimal dosing, including optimal dosing schedule 
5. No further need for the drug 
6. Drug-drug interactions 
7. Need for laboratory tests [e.g. therapeutic drug monitoring (TDM), 
laboratory values] 
8. Adverse effects (being experienced) (ADRs) 
9. Medical chart error (e.g. dose not stated) 
10. Compliance problems 
11. Patient education required (giving patient information on the 
physicians request, e.g. to avoid non-compliance) 
12. Information/therapy discussion (regarding a specific drug regimen 
for a patient) 
13. Others 
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RESULTS 
 The study included 212 patients, 54.4 % female, with a 
mean age 62.2 (±10.6 SD). On average, each patient used 4.8 
(range 0-14) medicines. All the recruited patients were 
monitored during the total length of their hospital stay. The 
average length of hospital stay was around 5.8 days ranging 
from 2 to 18 days as shown in Table 2.  
Table 2. Demographic Description of Recruited Patients 
Parameter  Patients with DRPs Patients without DRPs P-value 
 N= 187 N=25  
Average age in years (S.D) 65.4 (14.2) 58.1(5.9) 0.04* 
Age range 22-87 48-69  
Gender distribution (Female %) 101 (53.8%) 16 (64.0%) 0.07** 
Average number of medication taken (S.D) 5.1 (1.5) 2.9 (0.4) 0.02* 
Average length of hospital stay in days (S.D) 6.3 (2.1) 2.2 (0.9) 0.002* 
Average number of medical conditions (S.D) 4.1(2.7) 2.8 (1.1) 0.001* 
*Statistical level of significance, Mann-Whitney U-test, p<0.05 between the two groups, ** Statistical level of Significance at p<0.05, Chi-squared test. DRPs: Drugs Related 
Problems. SD: Standard deviation. P: Level of significance. 
 
Table 3. Type, Example and Acceptance Rate of Interventions Made 
 N=356 Acceptance Rate n (%)a Examples of Drugs involved 
Type of DRP n (%)  Full Partial b Rejected  
Non optimal dose  79  
(22.2) 
61 
(77.2) 
13 
(16.5) 
5 
(6.3) 
Antibiotics NSAIDs, ACEIs, spiranolactone  
Drug-Drug interaction 69 
(19.4) 
49 
(71.0) 
12 
(17.4) 
8 
(11.6) 
Carvedilol + salmeterol (β-blocker and β-agonist ). 
Aminophylline +Ceftriaxone (incompatible) 
Granisetone + Ciprofloxacin (arrhythmias)  
Need for laboratory tests  54 
(15.2) 
31 
(57.4) 
13 
(24.1) 
10 
(18.5) 
Warfarin, digoxtin, heparin, aminoglycosides  
Unnecessary drug  42  
(11.8)  
35 
(83.3) 
5 
(11.9) 
2 
(4.8) 
Enoxapirin, Rantidin, Famotidin, Opemrazole. Antibiotics 
Need additional drugs  26  
(7.3) 
17 
(65.4) 
6 
(23.1) 
3 
(11.5) 
Atorvastatin after MI, Analgesic for pain. Dopamine to 
achieve diuresis. Amlodipine for hypertension 
Adverse effect 18 
(5.0) 
10 
(55.6) 
2 
(1.1) 
6 
(33.3) 
Furosemide (hypokalemia) 
Ceftriaxone (cholecystitis) 
NSAIDs (↑risk of bleeding) 
Non optimal drug  16  
(4.5) 
9 
(56.2) 
3 
(18.8) 
4 
(25.0) 
Tetrahydrozoline-containing eye drops for treating dry eyes. 
Morphine replaced by pethidine. 
Amlodipine replaced by enalaprin 
No clear indication 14  
(3.9) 
11 
(78.6) 
1 
(7.1) 
2 
(14.3) 
Ceftriaxone and Metronidazole, Enoxapirin. (many cases with 
no indications)  
Medical Chart error  11 
(3.1) 
9 
(81.8) 
2 
(18.2) 
0 
(0.0) 
ISMN® (trade name for isosorbide mononitrate).NSAIDs, 
Antibiotics (missing the dose or route of administration 
Therapy discussion  11 
(3.1) 
8 
(72.7) 
2 
(18.2) 
1 
(9.1) 
IgG, Tigecycline, Trastuzumab  
(prepared by clinical pharmacist) 
Patient education  10  
(2.8) 
10 
(100.0) 
0 
(0.0) 
0 
(0.0) 
Alendronate, Methotrexate, Folic acid 
Compliance problems 6 
(1.7) 
5 
(83.3) 
1 
(16.7) 
0 
(0.0) 
Carbamazepine, Phenytion, Folic acid.  
a Acceptance rate of pharmacist advice regarding each DRP group by physicians or healthcare professionals. 
bAdvice accepted but not acted upon, or partially acted upon. 
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 The 212 recruited patients were using a total of 1018 
medicines classified according to ATC classification system. 
Cardiovascular agents accounted for the majority of the 
medications consumed by the participants (25%) followed 
by anti-infective (16%), alimentary tract and metabolism 
(12%), anticoagulants and antiplatelets (10%), anti-
inflammatory (10%) and gastrointestinal drugs. 
 The pharmacists identified 356 DRPs in 187 of the 212 
patients (mean per patient 1.9; SD 0.8). 
 Ceftriaxone, enoxaparin, warfarin, and digoxitin were the 
drugs causing most frequent DRPs. The drug groups causing 
most DRPs were J01A-antiifective agents, B01A-anti- 
thrombotic agents, M01A-non-steroidal anti-inflammatory 
agents and A02B-drugs for peptic ulcer disease.  
 Table 3 represents the most commonly reported DRPs. 
Among the detected problems, incorrect dosing regimen 
represented the highest percentage (22.2%) followed by 
drug-drug interaction (19.4 %), drugs that required 
therapeutic monitoring (15.2%), unnecessary drug therapy 
(11.8%) and the need for additional drug therapy (7.3%). 
 The majority (~90%) of the pharmacists’ interventions 
related to DRPs involved direct contact with the physician. 
For example, contraindications and adverse reactions were 
generally solved by immediate contact with the physician. 
Pharmacists were able to resolve some of the DRPs by 
themselves. This primarily included those related to 
adherence problems, and medications prescribed without 
indication. 
 Of 356 DRPs, 255 (71.6%) DRPs were solved 
immediately (i.e. “Full acceptance”). An additional 60 
(16.8%) were accepted as DRPs, but immediate action was 
not taken (i.e. ‘‘Partial acceptance’’). Pharmacist advice was 
rejected for 41 (11.5%) DRPs (Table 3).  
 Age, gender, type of department, number of medication 
and number of medical conditions were analyzed to 
determine whether they could predict the occurrence of 
DRPs. Multiple regression analysis found that number of 
medications (RR 1.99; 95% CI 1.31-3.76) and number of 
medical conditions (RR 1.81; 95% CI 1.11-3.13) 
independently predicted the number of DRPs. There was no 
relationship between age or gender and the number of DRPs 
identified (Table 4). 
DISCUSSION 
 The majority of patients have one or more DRPs in 
clinical departments in general hospitals. On average the 
pharmacists identified 1.9 DRPs per study patient. Our 
findings are well comparable with studies previously 
conducted in the European countries [1, 2, 28] revealed an 
average of 2.5 DRPs per patient. The little differences may 
be explained by different study populations. In consistence 
with our study, other researchers have also found high 
frequencies of inappropriate dosing [1, 29, 30-32], 
inappropriate drugs [33-35], need for laboratory tests [36] 
and need for additional drugs [37]. 
 Drug dosing was considered too high in several cases 
including: Paracetamol 4 grams/day, Ceftriaxone intravenous 
2g/day, Lactulose 30 ml/day and Spiranolactone 100mg in 
the presence of ACEI and heart failure. Ranitidine or 
Famotidine and Omeprazole combination represented the 
most unnecessary combination specially when used as 
prophylaxis against stress ulcer. 
 In this study, cardiovascular drugs are highly involved. 
However cardiovascular drugs were especially associated 
with probably unavoidable side effects. These problems 
could lead to early discontinuation of treatment which has 
been reported frequently as an important problem with 
cardiovascular preventive therapy such as antihypertensive 
and lipid lowering drugs. Gastrointestinal drugs such as 
laxatives and antacids were also highly involved, and have 
been reported as possible predictors of prescribing errors by 
Fijn et al. [38].  
 Among the 212 patients reviewed, 51 (24.0%) received 
one or more of those drugs described as having narrow 
therapeutic index and required careful monitoring. Out of 
those 51 patients, only 6 patients (11.8%) were monitored 
for those medications. This lack of monitoring can be 
Table 4. Variables Associated with Occurrence of Drug-related Problems (DRPs) 
 Univariate Analysis  Multivariate Analysis 
Variables RR  CI 95% P-Value RR  CI 95% P-Value 
Gender (female=1) 1.06 0.71-1.21 (0.3) --- ---- --- 
Age per 10 years 1.03 0.66-1.33 (0.3) --- ---- --- 
No. of medical conditions 2.1 1.21-3.45 (0.001) 1.81 1.11-3.13 (0.001) 
No. of medication used 2.4 1.70-3.99 (0.001) 1.99 1.31-3.76 (0.001) 
Department  
Rheumatology 
Surgical  
Internal medicine 
ICU 
 
1 
0.95 
0.90 
1.04 
 
0.78-1.11 
0.72-1.09 
0.84-1.22 
 
(0.11) 
(0.12) 
(0.08) 
 
0.87 
0.83 
0.98 
 
0.70-0.99 
0.66-1.01 
0.79-1.21 
 
(0.13) 
(0.06) 
(0.09) 
ICU: Intensive care unit. 
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attributed to several factors; the major will be cost related 
[36]. Not all the physicians were familiar with which drugs 
should be closely monitored and even those who were 
familiar did not know the availability of the monitoring tests 
in their hospital. When the physicians were verbally asked 
about the importance of therapeutic drug monitoring some of 
them believed that clinical manifestation would be the best 
indicator to count on rather than the drug plasma sample. 
 Regarding drug-drug interaction, there was no special 
pattern for the identified drug-drug interactions in the 
screened patients. Only major interactions as classified using 
the Lexi-comp software were reported. This included 
prescribing Granisetone together with the Ciprofloxacin. 
 The most commonly prescribed medications with no 
clear indication were metronidazole and ceftriaxone which 
were prescribed for a sole reason which is prophylaxis, 
regardless of the patient case and kidney or liver function. 
 The effectiveness of pharmacists' interventions can be 
evaluated by means of physicians acceptance rates of  
the pharmacists’ recommendations. Our study revealed 
71.8% acceptance and full implementation of pharmacists’ 
interventions. Previous studies report acceptance rates 
between 39% and 92% [39, 40]. This is probably due to 
different communication models when addressing DRPs. 
Direct communication between healthcare providers in 
general reveals higher acceptance rates than indirect contact, 
e.g. written reports [2]. This proactive approach may also 
have contributed to the high rate of problem-solving 
achieved in this study, as interventions were planned and 
executed during round discussion.  
 In general, 33.3% of the identified adverse drug effects 
and 25.0% of non-optimal prescribed drugs were not 
approved by the clinical teams, while proposed DRPs 
regarding “Unnecessary drug” and “no clear indication” 
were highly accepted by the physicians. This is possibly 
explained by the fact that most adverse effects were 
considered of minor clinical importance. Another 
explanation is that risk-benefit analyses have already been 
performed by physicians when prescribing the actual drugs 
and combinations. A previous study has reported that in 
32.1% of cases when an adverse drug event occurred and 
reported to a healthcare provider, the drug was continued as 
before, with no further intervention from the healthcare 
provider [41]. This may be explained by that the pharmacist 
considered the side effect to be tolerable and not avoidable. 
 The major findings included an indication of several 
factors associated with DRPs. The number of medical 
conditions and the number of medications prescribed were 
independently associated with the number of DRPs. This 
implies that poly-pharmacy and co-morbidities are major 
risk factors for experiencing DRPs, which is consistent  
with other studies [42, 43]. Furthermore, the number of 
medications and co-morbidities appear to be strong 
predictors for the development of certain DRPs such as drug-
drug interactions, need for laboratory tests, dosage problems 
and the need for additional drugs. 
 Future studies need to evaluate possible solutions that 
may prevent these drug related mistakes from happening. 
Some of the measures that may be considered include 
frequent chart reviews that may help identify DRP followed 
by communication of those DRP to respective physicians. 
Another measure may include bar codes for proper drug 
identification. Education and publicizing of the findings of 
this study may also help increase awareness in Palestinian 
hospitals. Finally, the study clearly indicates that the 
pharmacist may play an important role in identifying DRP. 
As such, effort needs to be made to increase opportunities 
for pharmacist support in drug treatment. 
LIMITATION 
 The main limitation is that the study is small and that a 
control group was not included. The process of identification 
of the DRPs depended mainly on an observational experience 
which is more subjective and may be a source of bias. 
Another limitation is that the study was restricted to two 
hospitals and therefore cannot be assumed that the results are 
representative of other hospitals. The intervention revealed a 
significant reduction in number of DRPs. However, effects 
on clinical endpoints and drugs costs were not examined, as 
this was beyond the scope of this study. Future research 
should focus on studying the optimal strategy to improve 
prescribing practices and monitoring, particularly among 
high-risk patients or patients taking high-risk medications. 
CONCLUSION  
 DRPs in general hospitals are frequent, serious and 
predictable. Most of the problems identified as DRPs by the 
pharmacists were accepted by the physicians and solved. 
Pharmacists in the hospital setting are well suited to identify 
and resolve DRPs. Policy-makers should consider 
implementing systematic medication reviews on a regular 
basis to achieve and maintain high-quality drug treatment in 
general hospitals. Future research should include clinical 
end-points to substantiate beneficial patient-related outcomes, 
e.g. reductions in side effects, and possible cost-savings.  
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